Global 2023 - Players, Regions, Product Types, Application & Forecast Analysis

Product Market size is rising upward in the past few years And it is estimated that the market will grow significantly in the forecasted period<table class='table'> <tr> <th>ATTRIBUTES</th> <th>DETAILS</th> </tr><tr> <td>STUDY PERIOD</td><td>2017-2030</td></tr><tr> <td>BASE YEAR</td><td>2023</td></tr><tr> <td>FORECAST PERIOD</td><td>2024-2030</td></tr><tr> <td>HISTORICAL PERIOD</td><td>2017-2022</td></tr><tr> <td>UNIT</td><td>VALUE (USD MILLION)</td></tr><tr> <td>KEY COMPANIES PROFILED</td><td>Vasudha Pharma, Arevipharma, Aspire Lifesciences, Ipca Lab, R. L. Fine Chem, Bal Pharma, Micro Lab, EstechPharma, Suanfarma</td></tr><tr> <td>SEGMENTS COVERED</td><td style='text-transform:capitalize;'>By Product Type - Purity≥98%, Purity≥99%<br>By Application - Ebastine Oral Solution, Ebastine Oral Tablet<br>By Sales Channels - Direct Channel, Distribution Channel<br>By Geography - North America, Europe, Asia-Pacific, South America, Middle East and Africa</td></tr></table>

近年来，产品市场体量呈上升趋势，据预测，在预测期内市场将显著增长。<table class='table'> <tr> <th>属性</th> <th>详情</th> </tr> <tr> <td>研究周期</td> <td>2017-2030</td> </tr> <tr> <td>基准年份</td> <td>2023</td> </tr> <tr> <td>预测周期</td> <td>2024-2030</td> </tr> <tr> <td>历史周期</td> <td>2017-2022</td> </tr> <tr> <td>单位</td> <td>价值（亿美元）</td> </tr> <tr> <td>涵盖的关键公司简介</td> <td>瓦苏达药厂、阿瑞维帕玛、阿斯派尔生命科学、伊普卡实验室、R. L. 精细化学、巴尔药厂、微实验室、埃斯特克药厂、顺安药厂</td> </tr> <tr> <td>涵盖的细分市场</td> <td style='text-transform:capitalize;'>按产品类型 - 纯度≥98%，纯度≥99%<br>按应用 - 阿司咪唑口服溶液，阿司咪唑口服片<br>按销售渠道 - 直接渠道，分销渠道<br>按地区 - 北美洲，欧洲，亚太地区，南美洲，中东和非洲</td> </tr> </table>